226 related articles for article (PubMed ID: 29998522)
1. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination.
Kåberg M; Navér G; Hammarberg A; Weiland O
J Viral Hepat; 2018 Dec; 25(12):1452-1461. PubMed ID: 29998522
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity.
Kåberg M; Edgren E; Hammarberg A; Weiland O
Scand J Gastroenterol; 2019 Mar; 54(3):319-327. PubMed ID: 30907178
[No Abstract] [Full Text] [Related]
4. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
5. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era.
Gahrton C; Navér G; Warnqvist A; Dalgard O; Aleman S; Kåberg M
Int J Drug Policy; 2024 Jun; 128():104433. PubMed ID: 38703622
[TBL] [Abstract][Full Text] [Related]
6. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.
Scott N; Sacks-Davis R; Pedrana A; Doyle J; Thompson A; Hellard M
J Viral Hepat; 2018 Dec; 25(12):1472-1480. PubMed ID: 30047625
[TBL] [Abstract][Full Text] [Related]
7. Significant decrease in injection risk behaviours among participants in a needle exchange programme.
Kåberg M; Karlsson N; Discacciati A; Widgren K; Weiland O; Ekström AM; Hammarberg A
Infect Dis (Lond); 2020 May; 52(5):336-346. PubMed ID: 32072841
[No Abstract] [Full Text] [Related]
8. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden.
Kågström E; Lannergård A; El Khosht J; Lörelius P; Månflod J; Strömdahl S
Harm Reduct J; 2023 Jun; 20(1):77. PubMed ID: 37328868
[TBL] [Abstract][Full Text] [Related]
10. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
11. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden.
Lindqvist K; Thorin Z; Kåberg M
Harm Reduct J; 2023 Jun; 20(1):72. PubMed ID: 37308951
[TBL] [Abstract][Full Text] [Related]
12. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
[TBL] [Abstract][Full Text] [Related]
14. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
[TBL] [Abstract][Full Text] [Related]
15. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
[TBL] [Abstract][Full Text] [Related]
16. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
Schulkind J; Stephens B; Ahmad F; Johnston L; Hutchinson S; Thain D; Ward Z; Vickerman P; Hickman M; Dillon JF
J Viral Hepat; 2019 May; 26(5):519-528. PubMed ID: 30422370
[TBL] [Abstract][Full Text] [Related]
17. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
[TBL] [Abstract][Full Text] [Related]
18. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
Bruggmann P; Grebely J
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
20. The effects of needle-sharing and opioid substitution therapy on incidence of hepatitis C virus infection and reinfection in people who inject drugs.
Aitken CK; Agius PA; Higgs PG; Stoové MA; Bowden DS; Dietze PM
Epidemiol Infect; 2017 Mar; 145(4):796-801. PubMed ID: 27927256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
